The efficacy of ibrutinib in the treatment of Richter syndrome

Mazie Tsang; Tait D. Shanafelt; Timothy G. Call; Wei Ding; Asher Chanan-Khan; Jose F. Leis; Grzegorz S. Nowakowski; Deborah Bowen; Michael Conte; Susan M. Schwager; Susan L. Slager; Neil E. Kay; Curtis A. Hanson; Sameer A. Parikh

doi:10.1182/blood-2014-12-610782

The efficacy of ibrutinib in the treatment of Richter syndrome

Mazie Tsang, Tait D. Shanafelt, Timothy G. Call, Wei Ding, Asher Chanan-Khan, Jose F. Leis, Grzegorz S. Nowakowski, Deborah Bowen, Michael Conte, Susan M. Schwager, Susan L. Slager, Neil E. Kay, Curtis A. Hanson, Sameer A. Parikh

Research output: Contribution to journal › Letter › peer-review

48 Scopus citations

Original language	English (US)
Pages (from-to)	1676-1678
Number of pages	3
Journal	Blood
Volume	125
Issue number	10
DOIs	https://doi.org/10.1182/blood-2014-12-610782
State	Published - 2015

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood-2014-12-610782

Cite this

@article{d1c7e080ab1d45e296b8a15099e514a7,

title = "The efficacy of ibrutinib in the treatment of Richter syndrome",

author = "Mazie Tsang and Shanafelt, {Tait D.} and Call, {Timothy G.} and Wei Ding and Asher Chanan-Khan and Leis, {Jose F.} and Nowakowski, {Grzegorz S.} and Deborah Bowen and Michael Conte and Schwager, {Susan M.} and Slager, {Susan L.} and Kay, {Neil E.} and Hanson, {Curtis A.} and Parikh, {Sameer A.}",

note = "Funding Information: This work was supported by National Institutes of Health, National Cancer Institute grants K23CA160345 (W.D.) and CA95241 (N.E.K.). S.A.P. is a recipient of the Mayo Clinic Department of Medicine Career Development Grant for Scholarly Clinicians. T.D.S. is a scholar of the Leukemia and Lymphoma Society. T.D.S. has received research funding from Genentech, GlaxoSmithKline, Cephalon, Hospira, Celgene, Jannsen, and Polyphenon E International. The remaining authors declare no competing financial interests. Funding Information: Conflict-of-interest disclosure: T.D.S. has received research funding from Genentech, GlaxoSmithKline, Cephalon, Hospira, Celgene, Jannsen, and Polyphenon E International. The remaining authors declare no competing financial interests. Funding Information: Acknowledgments: This work was supported by National Institutes of Health, National Cancer Institute grants K23CA160345 (W.D.) and CA95241 (N.E.K.). S.A.P. is a recipient of the Mayo Clinic Department of Medicine Career Development Grant for Scholarly Clinicians. T.D.S. is a scholar of the Leukemia and Lymphoma Society.",

year = "2015",

doi = "10.1182/blood-2014-12-610782",

language = "English (US)",

volume = "125",

pages = "1676--1678",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "10",

}

TY - JOUR

T1 - The efficacy of ibrutinib in the treatment of Richter syndrome

AU - Tsang, Mazie

AU - Shanafelt, Tait D.

AU - Call, Timothy G.

AU - Ding, Wei

AU - Chanan-Khan, Asher

AU - Leis, Jose F.

AU - Nowakowski, Grzegorz S.

AU - Bowen, Deborah

AU - Conte, Michael

AU - Schwager, Susan M.

AU - Slager, Susan L.

AU - Kay, Neil E.

AU - Hanson, Curtis A.

AU - Parikh, Sameer A.

N1 - Funding Information: This work was supported by National Institutes of Health, National Cancer Institute grants K23CA160345 (W.D.) and CA95241 (N.E.K.). S.A.P. is a recipient of the Mayo Clinic Department of Medicine Career Development Grant for Scholarly Clinicians. T.D.S. is a scholar of the Leukemia and Lymphoma Society. T.D.S. has received research funding from Genentech, GlaxoSmithKline, Cephalon, Hospira, Celgene, Jannsen, and Polyphenon E International. The remaining authors declare no competing financial interests. Funding Information: Conflict-of-interest disclosure: T.D.S. has received research funding from Genentech, GlaxoSmithKline, Cephalon, Hospira, Celgene, Jannsen, and Polyphenon E International. The remaining authors declare no competing financial interests. Funding Information: Acknowledgments: This work was supported by National Institutes of Health, National Cancer Institute grants K23CA160345 (W.D.) and CA95241 (N.E.K.). S.A.P. is a recipient of the Mayo Clinic Department of Medicine Career Development Grant for Scholarly Clinicians. T.D.S. is a scholar of the Leukemia and Lymphoma Society.

PY - 2015

Y1 - 2015

UR - http://www.scopus.com/inward/record.url?scp=84982170093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982170093&partnerID=8YFLogxK

U2 - 10.1182/blood-2014-12-610782

DO - 10.1182/blood-2014-12-610782

M3 - Letter

C2 - 25745187

AN - SCOPUS:84982170093

SN - 0006-4971

VL - 125

SP - 1676

EP - 1678

JO - Blood

JF - Blood

IS - 10

ER -

The efficacy of ibrutinib in the treatment of Richter syndrome

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this